Related Experiment Video
Updated: May 24, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation
Tousei Hashimoto1, Junnichi Ishii, Fumihiko Kitagawa
1Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Insights
High-mobility group box 1 (HMGB1) may predict cardiovascular death in patients with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI). Elevated HMGB1 levels on admission indicate a higher risk for mortality in these patients.
Area of Science:
- Cardiology
- Biomarkers
- Acute Coronary Syndromes
Background:
- High-mobility group box 1 (HMGB1) is a damage-associated molecular pattern molecule implicated in acute coronary syndrome (ACS) pathophysiology.
- Previous studies linked circulating HMGB1 to cardiac mortality in ST-segment elevation myocardial infarction.
- The prognostic significance of HMGB1 in unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI) remained unclear.
Purpose of the Study:
- To investigate the prognostic value of circulating HMGB1 concentrations in patients hospitalized for UA/NSTEMI.
- To determine if HMGB1 is an independent predictor of cardiovascular mortality in this patient cohort.
Main Methods:
- HMGB1, hsCRP, troponin I, and BNP levels were measured on admission in 258 UA/NSTEMI patients.
- Patients were followed for a median of 49 months to assess cardiovascular mortality.
- Cox regression analysis was used to identify independent predictors of mortality, adjusting for clinical factors.
Main Results:
- Cardiovascular death occurred in 14.7% of patients during follow-up.
- HMGB1, cardiac troponin I, Killip class >1, and age were independent predictors of cardiovascular mortality.
- Patients with elevated HMGB1 (≥ 2.4 ng/mL) exhibited significantly higher in-hospital and cardiovascular mortality rates compared to those with lower levels.
Conclusions:
- Circulating HMGB1 concentration upon admission is a potential and independent predictor of cardiovascular mortality in UA/NSTEMI patients.
- HMGB1 may serve as a valuable biomarker for risk stratification in patients hospitalized for UA/NSTEMI within 24 hours of symptom onset.
Objective:
High-mobility group box 1 (HMGB1) is a damage-associated molecular pattern molecule, which suggests a potential role of this protein in the pathophysiology of acute coronary syndrome (ACS). Circulating HMGB1 has been shown to be independently associated with cardiac mortality in ST-segment elevation myocardial infarction. However, its prognostic value remains unclear in unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI).
Methods:
HMGB1, high-sensitivity C-reactive protein (hsCRP), cardiac troponin I and B-type natriuretic peptide concentrations were measured on admission in 258 consecutive patients (mean age of 67 years) hospitalized for UA/NSTEMI within 24h (mean, 7.4h) of the onset of chest symptoms.
Results:
A total of 38 (14.7%) cardiovascular deaths, including 10 in-hospital deaths, occurred during a median follow-up period of 49 months after admission. In a stepwise Cox regression analysis including 19 well-known clinical predictors of ACS, HMGB1 [relative risk (RR) 3.24 per 10-fold increment; P = 0.0003], cardiac troponin I (RR 1.83 per 10-fold increment, P = 0.0007), Killip class>1 (RR 4.67, P = 0.0001) and age (RR 1.05 per 1-year increment, P = 0.03), but not hsCRP, were independently associated with cardiovascular mortality. In-hospital and cardiovascular mortality rates were higher in patients with increased HMGB1 (≥ 2.4 ng/mL of median value) than those without increased HMGB1 (6.3% vs. 1.5%, P = 0.04; and 23% vs. 6.9%, P = 0.0003).
Conclusion:
Circulating concentration of HMGB1 on admission may be a potential and independent predictor of cardiovascular mortality in patients hospitalized for UA/NSTEMI within 24h of onset.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Angina IV: Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations